Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + FOLFIRI vs Bevacizumab + FOLFIRI in mCRC
NCT07359456Phase 2Not yet recruiting
- Sponsor
- Unicancer
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in colorectal cancer (CRC), sponsored by Unicancer. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07359456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359456.